Welcome to BeOne

BeOne's medical website with resources for healthcare professionals and disease information for patients and caregivers.

Please confirm the option below that best describes you so we can direct you to appropriate resources and information.

I am a...

Healthcare Professional

hcp

Patient / Caregiver

patient

BeOne Employee

employee

I am from...

GLOBAL (ex-US) / EN

https://beonemedaffairs.com/

France / FR

https://beimedplus.com/fr/

Italy / IT

https://beonemedaffairs.com/it/

United States / US

https://beonemedaffairs.com/us/

GLOBAL (ex-US) / EN

https://beimedplus.com/pts-en/

Italy / IT

https://beonemedaffairs.com/pts-it/

Skip to content

Login / Register

Congress Resources
BeGenius
Publications
Pipeline
Molecules
Clinical Trials
Disease Education
- Hematologic Malignancies
- Solid Tumors

Select Your Location:

Global

What are the latest advances and key challenges in first-line IO treatment of ES-SCLC?

Prof. Anne-Marie Dingemans

Video

6 Nov 2025

REPORT AN ADVERSE EVENT

adverse_events@beonemed.com
Contact Us by Phone

REPORT A PRODUCT COMPLAINT

productcomplaints@beonemed.com
Contact Us by Phone

This website is intended for Healthcare Professionals for scientific information exchange purposes only, not for advertising purposes, and does not constitute commercial promotion of any product or recommendation on diagnosis and treatments.

The website may contain information about products or indications that have not yet been approved in your country; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

The safety and efficacy of investigational products or uses may not have been established. Because of the uncertainty of clinical trials, there is no guarantee that compounds will receive regulatory approval and become commercially available for the uses being investigated.

REPORT AN ADVERSE EVENT

adverse_events@beonemed.com
Contact Us by Phone

REPORT A PRODUCT COMPLAINT

productcomplaints@beonemed.com
Contact Us by Phone

Privacy Policy
Terms of Use

© BeOne Medicines I GmbH 2025.

You're now leaving the website www.beonemedaffairs.com

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave beonemedaffairs.com website. The link will take you to another BeOne website, the content of which is subject to the locally applicable laws and regulations.

BeOne Medicines I GmbH makes no representation that the information provided on the website is suitable or available for use or access in locations outside the country for which the website is intended.

Please ensure that you belong to the target group of the content provided on the linked website and that your access to it complies with the applicable laws and regulations.

No, want to go back Yes, I would like to continue

You're now leaving the website www.beonemedaffairs.com

This link is provided for information purposes only. You’ll be leaving Beonemedaffairs.com You will be leaving www.beonemedaffairs.com and accessing a third-party websiteover which BeOne Medicines I GmbH has no control or influence.

BeOne Medicines I GmbH makes no representations about its content or availability in your location, and declines any responsibility for third-party information, data usage policies, and personal data processing. By proceeding, you acknowledge you are part of the intended audience of the third-party website and comply with applicable laws.

This link will take you to a third-party website outside of Beonemedaffairs.com. BeOne Medicines I GmbH has no control over this website and makes no representations about its content or availability in your location. We decline any responsibility for third-party information, data usage policies, and personal data handling. By proceeding, you confirm you’re part of the intended audience and comply with applicable laws. Do you want to leave Beonemedaffairs.com?

Do you want to leave the www.beonemedaffairs.com website?

No, want to go back Yes, I would like to continue